home / stock / atnx / atnx news

ATNX News and Press, Athenex Inc. From 06/22/20

Stock Information
Company Name: Athenex Inc.
Stock Symbol: ATNX
Market: NASDAQ
Menu
ATNX ATNX Quote ATNX Short ATNX News ATNX Articles ATNX Message Board
Get ATNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ATNX - Athenex Announces $225 Million Loan Agreement with Oaktree

BUFFALO, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and re...
ATNX - Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer

BUFFALO, N.Y. and CHICAGO , June 13, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that Athenex Oncology, a U.S. ba...

ATNX - Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program

BUFFALO, N.Y., May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today presented interim data from an ongoing Phase II clinical tria...

ATNX - Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

BUFFALO, N.Y., May 19, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will par...
ATNX - Athenex, Inc. (ATNX) CEO Dr. Johnson Lau on Q1 2020 Results - Earnings Call Transcript

Athenex, Inc. (ATNX) Q1 2020 Results Conference Call May 07, 2020 8:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors Dr. Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Dr. Rudolf Kwan - Chief Medical Officer Randoll Sze - Chief Fin...

ATNX - Athenex, Inc. (ATNX) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. Athenex, Inc.   (NASDAQ: ATNX) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading

ATNX - Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update

Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today at 8:00am Eastern Time BUFFALO, N.Y., May 07, 2020 (GLOB...
ATNX - Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for i...

ATNX - Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020

BUFFALO, N.Y., April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first ...

ATNX - Athenex Provides an Update on Oral Paclitaxel FDA Meeting

BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently parti...
Previous 10 Next 10